

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Interventional procedure overview of selective dorsal rhizotomy for spasticity in cerebral palsy

The aim of selective dorsal rhizotomy is to ease muscle spasticity and improve mobility in people with cerebral palsy. It involves cutting nerves in the lower spine that are responsible for muscle rigidity.

Introduction

The National Institute for Health and Clinical Excellence (NICE) has prepared this overview to help members of the Interventional Procedures Advisory Committee (IPAC) make recommendations about the safety and efficacy of an interventional procedure. It is based on a rapid review of the medical literature and specialist opinion. It should not be regarded as a definitive assessment of the procedure.

Date prepared

This overview was prepared in July 2010.

Procedure name

- Selective dorsal rhizotomy for spasticity in cerebral palsy
- Limited dorsal rhizotomy
- Selective posterior rhizotomy

Specialty societies

- British Orthopaedic Association (BOA)
- British Paediatric Neurosurgical Group (BPNG)
- British Society for Children's Orthopaedic Surgery
- Society of British Neurological Surgeons (SBNS).

Description

Indications and current treatment

Cerebral palsy describes a group of permanent brain disorders originating during fetal development, birth or early childhood. It is associated with abnormalities of movement, balance and posture, and people with cerebral palsy can have language and visual difficulties. Lower limb spasticity affects 80% of people with cerebral palsy, which can impair walking and sitting, and can cause discomfort, cramps and spasms.

Current treatments for lower limb spasticity include oral muscle relaxant medication, orthotic devices, physiotherapy, and repeated intramuscular injections of botulinum toxin. Surgical procedures include tendonotomy, tendon lengthening, peripheral neurotomy, osteotomy, electrical stimulation of the muscles or dorsal spinal cord, and continuous intrathecal baclofen infusion.

What the procedure involves

The aim of selective dorsal rhizotomy is to achieve a long-term reduction in sensory input to the sensory–motor reflex arcs responsible for increased muscle tone, by dividing some of the lumbar sensory nerve roots.

Muscle tone (tension) is normally determined by:

- a sensory–motor reflex comprising input from sensory nerves in the muscles to spinal motor nerves, which in turn send contracting stimuli to the muscles, increasing muscular tone, **and**
- modulation (mainly down-regulation) of this reflex by nuclei in the brain.

In people with central nervous system dysfunction (as is the case in cerebral palsy) the ‘damping down’ effect of brain nuclei can be diminished. In these people muscle tone is largely determined only by the sensory–motor reflex arc between the affected muscles and the (under-regulated) spinal cord, resulting in abnormally high muscular tone (spasticity).

With the patient under general anaesthesia, a laminectomy of one or more vertebrae is performed to expose the dural sac, which is opened to display the spinal conus with or without the cauda equina. Intraoperative neurophysiological assessment is commonly used to identify the sensory nerve rootlets judged to be most responsible for the excess motor tone. Selected sensory rootlets are divided, preserving some sensory supply and the motor roots responsible for voluntary movements.

Intensive physiotherapy and aftercare is usually given for several months after the procedure. Patients who were previously able to walk may have to learn different walking skills.

Instruments to assess efficacy

A range of validated instruments are used to evaluate the efficacy of spasticity treatments including:

- Modified Ashworth Scale: measures spasticity and improvement in tone on a 5-point scale (0 = no increase in muscle tone, 5 = affected part(s) rigid in flexion or extension).
- Gross Motor Function Classification System (GMFCS): a 5-level classification system that describes the gross motor function of children with cerebral palsy on the basis of their self-initiated movement.
- Gross Motor Function Measure (GMFM): evaluates change in gross motor function in children with cerebral palsy. The current version has 66 items covering: lying, rolling, sitting, crawling, kneeling, standing, walking, running and jumping. Each item is scored on a 4-point scale. A higher score indicates good gross motor functioning.
- Gross Motor Performance Measure (GMPM): used to evaluate quality of movement in children with cerebral palsy. Twenty items assess alignment, coordination, dissociated movement, stability and weight shift. Each item is scored on a 5-point scale.
- Pediatric Evaluation of Disability Inventory (PEDI): measures self-care, mobility and social skills using scores obtained by a combination of parent interview and direct observation. Scores range from 0 to 100 with a higher score indicating greater independence and less reliance on the caregiver.

Literature review

Rapid review of literature

The medical literature was searched to identify studies and reviews relevant to selective dorsal rhizotomy for spasticity in cerebral palsy. Searches were conducted of the following databases, covering the period from their commencement to 7 July 2009 and updated 27 July 2010: MEDLINE, PREMEDLINE, EMBASE, Cochrane Library and other databases. Trial registries and the Internet were also searched. No language restriction was applied to the searches (see appendix C for details of search strategy). Relevant published studies identified during consultation or resolution that are published after this date may also be considered for inclusion.

The following selection criteria (table 1) were applied to the abstracts identified by the literature search. Where selection criteria could not be determined from the abstracts the full paper was retrieved.

Table 1 Inclusion criteria for identification of relevant studies

Characteristic	Criteria
Publication type	Clinical studies were included. Emphasis was placed on identifying good quality studies. Abstracts were excluded where no clinical outcomes were reported, or where the paper was a review, editorial, or a laboratory or animal study. Conference abstracts were also excluded because of the difficulty of appraising study methodology, unless they reported specific adverse events that were not available in the published literature.
Patient	Patients with spasticity in cerebral palsy
Intervention/test	Selective dorsal rhizotomy
Outcome	Articles were retrieved if the abstract contained information relevant to the safety and/or efficacy.
Language	Non-English-language articles were excluded unless they were thought to add substantively to the English-language evidence base.

List of studies included in the overview

This overview is based on 1048 patients from 1 meta-analysis^{1, 6} non-randomised comparative studies^{2, 3, 4, 5, 6, 7} and 6 case series^{8, 9, 10, 11, 12, 13}.

There is some overlap between the 30 and 14 patients in the last 2 case series.

Other studies that were considered to be relevant to the procedure but were not included in the main extraction table (table 2) have been listed in appendix A.

Table 2 Summary of key efficacy and safety findings on selective dorsal rhizotomy for spasticity in cerebral palsy

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments												
<p>McLaughlin J (2002)¹</p> <p>Meta analysis (three RCTs)</p> <p>USA and Canada</p> <p>Recruitment period: RCTs up to December 2000.</p> <p>Study population: Children with spastic diplegia CP – inclusion criteria varied between study sites</p> <p>n = 90 (number having SDR not stated)</p> <p>Age: 5.5 years (mean)</p> <p>Sex: 53% male</p> <p>Patient selection criteria: see above</p> <p>Technique: SDR and physiotherapy (the use of electrophysiological monitoring to select dorsal roots for sectioning varied across the studies) versus physiotherapy alone.</p> <p>Follow-up: 9 months (1 study) and 12 months (2 studies)</p> <p>Conflict of interest/source of funding: funding provided by a foundation</p>	<p>Number of patients analysed: 90</p> <p>Operative parameters</p> <p>There was a statistically significant inverse correlation between the baseline GMFM-66 score and the percentage of dorsal rootlets cut ($p = 0.0002$). This was independent of study site.</p> <p>Clinical outcomes</p> <p>SDR multivariate analysis</p> <table border="1" data-bbox="544 698 1094 1041"> <thead> <tr> <th data-bbox="544 698 734 731">Outcome</th><th data-bbox="734 698 967 731">Change scores*</th><th data-bbox="967 698 1094 731">p value</th></tr> </thead> <tbody> <tr> <td data-bbox="544 731 734 829">Modified Ashworth Scale</td><td data-bbox="734 731 967 829">−1.23 (indicating a reduction in spasticity)</td><td data-bbox="967 731 1094 829">< 0.001</td></tr> <tr> <td data-bbox="544 829 734 959">GMFM</td><td data-bbox="734 829 967 959">4.53 (indicating increase in gross motor function)</td><td data-bbox="967 829 1094 959">0.002</td></tr> <tr> <td data-bbox="544 959 734 1041">GMFM-66</td><td data-bbox="734 959 967 1041">2.66 (indicating increase in gross motor function)</td><td data-bbox="967 959 1094 1041">0.002</td></tr> </tbody> </table> <p>*assume change scores relate to change from baseline, although this is unclear in the paper [IP analyst]</p> <p>A weak inverse correlation was found between the percentage of dorsal root tissue cut and change in Modified Ashworth Scale ($p = 0.03$) and GMFM score ($p < 0.001$).</p> <p>A small but statistically significant benefit of SDR and physiotherapy over physiotherapy was found. GMFM scores improved by 4% in the physiotherapy-only groups and 8% in the SDR plus physical therapy groups (data read from figure) ($p = 0.008$).</p> <p>It is not clear whether this benefit was clinically important.</p>	Outcome	Change scores*	p value	Modified Ashworth Scale	−1.23 (indicating a reduction in spasticity)	< 0.001	GMFM	4.53 (indicating increase in gross motor function)	0.002	GMFM-66	2.66 (indicating increase in gross motor function)	0.002	<p>No safety data from the primary studies is presented.</p>	<p>Reported in table 2 in the original overview</p> <p>Follow-up issues: Completeness of follow-up is not reported</p> <p>Study design issues: Medline, Cochrane and meeting abstracts searched for RCTs up to December 2000. No further details of search strategy provided.</p> <p>Multiple regression undertaken to assess factors of treatment group, study site, age, sex, birth weight, ambulatory status, and baseline clinical scores.</p> <p>In one study less dorsal root tissue was transected (25%) than in the other two studies (41% and 45%).</p> <p>Used two measures of gross motor function: GMFM and GMFM-66 (updated version).</p> <p>Functional GMFM outcome scores were assessed blindly in all patients.</p> <p>Method for data pooling used – blocked Wilcoxon's test.</p> <p>Study population issues: Baseline data: mean gestational age = 31.7 weeks, mean birth weight = 1849 g, prenatal cause of CP = 87% (78/90), baseline GMFM score = 62.5, proportion who were non-ambulatory = 57%. No difference in baseline characteristics between the two groups.</p> <p>Other issues: Primary researcher was also the author of one of the studies included, allowing for analysis of unpublished raw data, and ability to recalculate variables, but potential subjectivity.</p>
Outcome	Change scores*	p value													
Modified Ashworth Scale	−1.23 (indicating a reduction in spasticity)	< 0.001													
GMFM	4.53 (indicating increase in gross motor function)	0.002													
GMFM-66	2.66 (indicating increase in gross motor function)	0.002													

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG, electrophysiological guidance; GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP, intrathecal baclofen pumps; MDT, multidisciplinary team; PROM, passive range of movement; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments																				
<p>Kan P (2008)²</p> <p>Non-randomised comparative study</p> <p>USA</p> <p>Recruitment period: SDR group: up to 1997 ITBP group: 1997 onwards</p> <p>Study population: SDR group: children with severe spasticity with GMFCS score 3+ ITBP group: children matched by age and GMFCS score.</p> <p>n = 142 (71 vs 71) Age: 5.6 years (mean) Sex: not reported</p> <p>Patient selection criteria: see above</p> <p>Technique: SDR (description of method not reported) vs ITBP implantation (infusion started at 50 micrograms/day and doses then titrated to achieve maximal reduction in spasticity in each individual. Mean: 274 micrograms/day).</p> <p>Follow-up: 1 year</p> <p>Conflict of interest/source of funding: not reported</p>	<p>Number of patients analysed: 142 (71 vs 71)</p> <table border="1"> <thead> <tr> <th>Outcome</th> <th>SDR (n = 71)</th> <th>ITBP (n = 71)</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>Improvement in tone Modified Ashworth Scale</td> <td>-2.52</td> <td>-1.23</td> <td>< 0.0001</td> </tr> <tr> <td>Lower extremity PROM</td> <td>-0.77</td> <td>-0.39</td> <td>0.0138</td> </tr> <tr> <td>GMFCS</td> <td>-0.66</td> <td>-0.08</td> <td>< 0.0001</td> </tr> <tr> <td>Proportion requiring subsequent orthopaedic procedures (%)</td> <td>19.1</td> <td>40.8</td> <td>0.0106</td> </tr> </tbody> </table> <p>Patient satisfaction at 1 year SDR group: 93.5% satisfied (actual numbers not reported) ITBP group: 95.8% satisfied (actual numbers not reported) (p = 0.71)</p>	Outcome	SDR (n = 71)	ITBP (n = 71)	p value	Improvement in tone Modified Ashworth Scale	-2.52	-1.23	< 0.0001	Lower extremity PROM	-0.77	-0.39	0.0138	GMFCS	-0.66	-0.08	< 0.0001	Proportion requiring subsequent orthopaedic procedures (%)	19.1	40.8	0.0106	<p>Not reported</p>	<p>Follow-up issues: Completeness of follow-up is not reported</p> <p>Study design issues: Prospective data collection Only children who had SDR before introduction of ITBP were eligible to avoid selection bias. Authors state that since ITBP was introduced, SDR is only performed in a small number of select patients. Authors note that they were not able to control for comorbidities, concurrent medication and postoperative physical therapy which might have had an impact on the results.</p> <p>Study population issues: Proportion of dorsal nerve rootlets divided in the SDR group: 50–60%.</p>
Outcome	SDR (n = 71)	ITBP (n = 71)	p value																				
Improvement in tone Modified Ashworth Scale	-2.52	-1.23	< 0.0001																				
Lower extremity PROM	-0.77	-0.39	0.0138																				
GMFCS	-0.66	-0.08	< 0.0001																				
Proportion requiring subsequent orthopaedic procedures (%)	19.1	40.8	0.0106																				

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings						Key safety findings	Comments																																																					
<p>Engsberg JR (2006)³</p> <p>Non-randomised comparative study USA Recruitment period: not reported</p> <p>Study population: SDR and physical therapy group: ambulatory children with spastic diplegic CP enrolled through one SDR clinic; physical therapy-only group: ambulatory children with spastic diplegic CP found through local and national adverts; Controls: age-matched children with no disabilities recruited by contacting parents within the hospital community.</p> <p>n = 108 (31 vs 37 vs 40)</p> <p>Age: SDR group: 9 years (mean); physical therapy group: 9.7 years (mean); controls: 9.4 years</p> <p>Sex: SDR group: 48.4% (15/31) male; physical therapy group: 51.4% (19/37) male; controls: 52.5% (21/40) male</p> <p>Patient selection criteria: patients aged 4+ years with spastic diplegic CP with level I to III GMFCS, able to walk, minimum level of cognitive skills for active participation, no surgical intervention in the last year or Botox/casting procedures in last 6 months, hypertonicity of lower extremities, exaggerated deep-tendon leg reflex, Babinski sign and abnormal posture when sitting, standing and walking. Exclusions: children with motor deficits resulting from neurological injury or illness beginning after the first month of life and those with malformation of the nervous system. Patients with moderate to severe dystonia, athetosis, ataxia and severe cognitive delay were also excluded.</p> <p>Technique: SDR plus physical therapy (electrical stimulation was used to grade a reflex response from the lower extremity muscles and rootlets were cut according to the response) versus physical therapy only versus a control group (age-matched children with no disabilities).</p> <p>Follow-up: 20 months</p> <p>Conflict of interest/source of funding: funded by the National Institute of Neurological Disorders and Stroke</p>	<p>Number of patients analysed: 108 (31 vs 37 vs 40)</p> <p>SDR group: n = 31 for spasticity outcome n = 29 for other outcomes, physical therapy only n = 37 for spasticity outcome (n = 36) for other outcomes. <i>Italics indicates outcomes for which there was a significant ($p < 0.05$) differences in change from baseline to follow-up between the two (SDR+PT and PT) groups.</i></p> <table border="1" data-bbox="861 518 1643 1274"> <thead> <tr> <th rowspan="2">Outcome</th> <th colspan="2">SDR + physical therapy</th> <th colspan="2">Physical therapy only</th> <th rowspan="2">Controls (n = 40)</th> </tr> <tr> <th>Pre-op</th> <th>20 months</th> <th>Pre-op</th> <th>20 months</th> </tr> </thead> <tbody> <tr> <td>Knee spasticity (measured with isokinetic dynamometer)</td> <td>0.008‡</td> <td>0.002*</td> <td>0.01</td> <td>0.006</td> <td>0.003</td> </tr> <tr> <td>Maximum knee flexor strength (torque) scores (nm/kg)</td> <td>0.52</td> <td>0.64</td> <td>0.54</td> <td>0.66‡*</td> <td>0.92</td> </tr> <tr> <td>Maximum knee extensor strength (torque) scores (nm/kg)</td> <td>0.86</td> <td>1.14*</td> <td>0.92</td> <td>1.06‡</td> <td>1.66</td> </tr> <tr> <td>Gait speed (cm/sec)†</td> <td>81‡</td> <td>101*</td> <td>91‡</td> <td>93‡</td> <td>113</td> </tr> <tr> <td>Stride length (cm)</td> <td>79</td> <td>96*</td> <td>85</td> <td>90</td> <td>110</td> </tr> <tr> <td>Cadence (steps/min)</td> <td>122</td> <td>126</td> <td>129</td> <td>124</td> <td>124</td> </tr> <tr> <td>Knee flexor/extensor ROM†</td> <td>44‡</td> <td>52‡*</td> <td>45‡</td> <td>47‡</td> <td>61</td> </tr> <tr> <td>GMFM</td> <td>87</td> <td>92*</td> <td>89</td> <td>91*</td> <td>—</td> </tr> </tbody> </table> <p>*$p < 0.05$ comparing with pre-op; † $p < 0.05$ for comparisons of difference from baseline to follow-up between the SDR+PT and the PT groups; ‡ $p < 0.05$ comparing with control group</p>	Outcome	SDR + physical therapy		Physical therapy only		Controls (n = 40)	Pre-op	20 months	Pre-op	20 months	Knee spasticity (measured with isokinetic dynamometer)	0.008‡	0.002*	0.01	0.006	0.003	Maximum knee flexor strength (torque) scores (nm/kg)	0.52	0.64	0.54	0.66‡*	0.92	Maximum knee extensor strength (torque) scores (nm/kg)	0.86	1.14*	0.92	1.06‡	1.66	Gait speed (cm/sec)†	81‡	101*	91‡	93‡	113	Stride length (cm)	79	96*	85	90	110	Cadence (steps/min)	122	126	129	124	124	Knee flexor/extensor ROM†	44‡	52‡*	45‡	47‡	61	GMFM	87	92*	89	91*	—	Not reported	<p>Follow-up issues: Nine other children with CP were originally included in the study but dropped out (5 in SDR + physical therapy group and 4 in the physical therapy only group).</p> <p>Study design issues: Prospective study</p> <p>Study population issues: No significant differences between the three groups for age, weight and sex. No significant differences between the two CP groups for GMFCS level and gait status. The percentage of dorsal nerve rootlets sectioned in the SDR group was not reported.</p>
Outcome	SDR + physical therapy		Physical therapy only		Controls (n = 40)																																																								
	Pre-op	20 months	Pre-op	20 months																																																									
Knee spasticity (measured with isokinetic dynamometer)	0.008‡	0.002*	0.01	0.006	0.003																																																								
Maximum knee flexor strength (torque) scores (nm/kg)	0.52	0.64	0.54	0.66‡*	0.92																																																								
Maximum knee extensor strength (torque) scores (nm/kg)	0.86	1.14*	0.92	1.06‡	1.66																																																								
Gait speed (cm/sec)†	81‡	101*	91‡	93‡	113																																																								
Stride length (cm)	79	96*	85	90	110																																																								
Cadence (steps/min)	122	126	129	124	124																																																								
Knee flexor/extensor ROM†	44‡	52‡*	45‡	47‡	61																																																								
GMFM	87	92*	89	91*	—																																																								

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG, electrophysiological guidance; GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP, intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy																																																																																																							
Study details	Key efficacy findings				Key safety findings	Comments																																																																																																	
Wong A M K (2005) ⁴ Non-randomised comparative study Taiwan Recruitment period: not reported Study population: ambulatory children with spastic diplegia CP and healthy control children. n = 81 (20 vs 22 vs 20 vs 19) Age: SDR group: 5.4 years (mean), BTA group: 4.9 years (mean), rehabilitation group: 5 years (mean) and control group: 5.1 years (mean) Sex: 56.3% (45/80) male Patient selection criteria: children with CP had received regular rehabilitation for 6+ months with good compliance. CP patients had to be able to walk with a spastic gait, have bilateral spasticity without noticeable fixed contracture and have an Modified Ashworth Scale score of 2 or 3. Exclusions: children with Modified Ashworth Scale scores 1 and 4, significant leg length discrepancy, previous surgery of lower limbs or presence of athetoid movements. Technique: SDR (description of method not reported) vs BTA injection vs rehabilitation only vs controls (all patients with CP received regular rehabilitation therapy for 6 months before baseline). Follow-up: 20 months Conflict of interest/source of funding: Study supported by a national grant.	<p>Number of patients analysed: 81 (20 vs 22 vs 20 vs 19)</p> <p>Gait analysis</p> <table border="1"> <thead> <tr> <th>Group</th> <th>Baseline</th> <th>3 months</th> <th>p value</th> <th>20 months</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>Gait velocity (% body height/sec)</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>SDR</td> <td>33.5</td> <td>25.3</td> <td>< 0.05</td> <td>38.9</td> <td>< 0.05*</td> </tr> <tr> <td>BTA</td> <td>31.3</td> <td>35.7</td> <td>N/S</td> <td>32.5</td> <td>N/S</td> </tr> <tr> <td>Rehab</td> <td>35.5</td> <td>36.6</td> <td>N/S</td> <td>40.3</td> <td>N/S</td> </tr> <tr> <td>Control</td> <td>66.2</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Gait cadence (steps/min)</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>SDR</td> <td>88.5</td> <td>76.4</td> <td>N/S</td> <td>94.9</td> <td>N/S</td> </tr> <tr> <td>BTA</td> <td>92.0</td> <td>100.8</td> <td>N/S</td> <td>92.8</td> <td>N/S</td> </tr> <tr> <td>Rehab</td> <td>93.0</td> <td>90.0</td> <td>N/S</td> <td>85.6</td> <td>< 0.05*</td> </tr> <tr> <td>Control</td> <td>118.6</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Step length (% body height)</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>SDR</td> <td>21.4</td> <td>16.0</td> <td>N/S</td> <td>27.8</td> <td>< 0.01*</td> </tr> <tr> <td>BTA</td> <td>26.0</td> <td>26.2</td> <td>N/S</td> <td>24.7</td> <td>N/S</td> </tr> <tr> <td>Rehab</td> <td>25.6</td> <td>26.0</td> <td>N/S</td> <td>25.2</td> <td>N/S</td> </tr> <tr> <td>Control</td> <td>35.0</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table> <p>*Comparison with 3-month results</p> <p>The BTA group showed a statistically significant improvement in gait velocity over baseline score at 6 months, $38.7 \pm 12.4\%$ of body height per second and $31.3 \pm 10.2\%$ of body height per second ($p < 0.05$) but the difference did not persist past 12 months.</p> <p>The SDR group showed a significant deterioration in gait velocity at 3 months $25.3 \pm 12.0\%$ of body height per second vs $33.5 \pm 12.8\%$ of body height per second at baseline. However this score recovered at 6 months and was better than baseline at 12- and 20-month follow-up (not a significant difference).</p>				Group	Baseline	3 months	p value	20 months	p value	Gait velocity (% body height/sec)						SDR	33.5	25.3	< 0.05	38.9	< 0.05*	BTA	31.3	35.7	N/S	32.5	N/S	Rehab	35.5	36.6	N/S	40.3	N/S	Control	66.2	-	-	-	-	Gait cadence (steps/min)						SDR	88.5	76.4	N/S	94.9	N/S	BTA	92.0	100.8	N/S	92.8	N/S	Rehab	93.0	90.0	N/S	85.6	< 0.05*	Control	118.6	-	-	-	-	Step length (% body height)						SDR	21.4	16.0	N/S	27.8	< 0.01*	BTA	26.0	26.2	N/S	24.7	N/S	Rehab	25.6	26.0	N/S	25.2	N/S	Control	35.0	-	-	-	-	No safety data were presented in the study report	<p>Reported in table 2 in the original overview</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> • Completeness of follow-up not reported. <p>Study design issues:</p> <ul style="list-style-type: none"> • Parents chose therapy group. • Unclear how healthy controls were recruited. • No details of blinding of outcomes assessors. • Outcomes assessed by a computer-assisted gait analysis system measuring gait velocity, cadence, and step length (corrected for patient height) • No between-groups analysis was performed (only within groups). <p>Study population issues:</p> <ul style="list-style-type: none"> • Proportion of patients relying on walking aid = 51%. • No statistically significant difference between groups in terms of age, height, weight, sex, ambulation ability, or other baseline gait parameters. • Percentage dorsal nerve rootlets sectioned in the SDR group was not reported. <p>Other issues:</p> <ul style="list-style-type: none"> • During the study period SDR treatment costs were paid for by insurance while BTA was not. • Further study of SDR in children in whom repeated BTA injection produced a ceiling effect may be warranted. 	
Group	Baseline	3 months	p value	20 months	p value																																																																																																		
Gait velocity (% body height/sec)																																																																																																							
SDR	33.5	25.3	< 0.05	38.9	< 0.05*																																																																																																		
BTA	31.3	35.7	N/S	32.5	N/S																																																																																																		
Rehab	35.5	36.6	N/S	40.3	N/S																																																																																																		
Control	66.2	-	-	-	-																																																																																																		
Gait cadence (steps/min)																																																																																																							
SDR	88.5	76.4	N/S	94.9	N/S																																																																																																		
BTA	92.0	100.8	N/S	92.8	N/S																																																																																																		
Rehab	93.0	90.0	N/S	85.6	< 0.05*																																																																																																		
Control	118.6	-	-	-	-																																																																																																		
Step length (% body height)																																																																																																							
SDR	21.4	16.0	N/S	27.8	< 0.01*																																																																																																		
BTA	26.0	26.2	N/S	24.7	N/S																																																																																																		
Rehab	25.6	26.0	N/S	25.2	N/S																																																																																																		
Control	35.0	-	-	-	-																																																																																																		

<p>Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy</p>																				
Study details	Key efficacy findings		Key safety findings	Comments																
<p>Steinbok P (2009)⁵</p> <p>Non-randomised comparative study</p> <p>Canada</p> <p>Recruitment period: not reported</p> <p>Study population: children with spastic diplegia CP</p> <p>n = 44 (22 vs 22)</p> <p>Age: EPG group: 5.2 years (mean); No EPG group: 5.7 years (mean)</p> <p>Sex: not reported</p> <p>Patient selection criteria: all children who had SDR without EPG and matched controls who had SDR with EPG</p> <p>Technique: SDR with EPG vs SDR without EPG (all multilevel laminectomies from L1 to S1)</p> <p>Follow-up: 1 year</p> <p>Conflict of interest/source of funding: not reported</p>	<p>Number of patients analysed: 44 (22 vs 22)</p> <p><u>Change in score from baseline to 1-year follow-up:</u></p> <table border="1"> <thead> <tr> <th></th><th>EPG group (n = 22)</th><th>No EPG group (n = 22)</th><th>p value</th></tr> </thead> <tbody> <tr> <td>GMFCS</td><td>0.14</td><td>0.09</td><td>0.764</td></tr> <tr> <td>Ashworth hip adductors</td><td>1.2</td><td>0.9</td><td>0.307</td></tr> <tr> <td>ROM hip abductors</td><td>5.4</td><td>4.8</td><td>0.825</td></tr> </tbody> </table>			EPG group (n = 22)	No EPG group (n = 22)	p value	GMFCS	0.14	0.09	0.764	Ashworth hip adductors	1.2	0.9	0.307	ROM hip abductors	5.4	4.8	0.825	<p>No safety data were presented in the study report</p>	<p>Follow-up issues:</p> <ul style="list-style-type: none"> • Completeness of follow-up not reported. <p>Study design issues:</p> <ul style="list-style-type: none"> • Retrospective study. • Patient in the no-EPG group were matched to patients who had EPG with respect to GMFCS and age (however the authors also state that the controls were chosen randomly). • No details of blinding of outcome assessors. <p>Study population issues:</p> <ul style="list-style-type: none"> • Populations were no different at baseline in terms of GMFCS Ashworth and ROM scores. • Mean % of L2 to S1 dorsal roots cut: EPG group: 56.8; no EPG group: 52.8 (p = 0.12) • Operating time: EPG group: 3.55 hours; no EPG group: 3.23 hours (p = 0.006)
	EPG group (n = 22)	No EPG group (n = 22)	p value																	
GMFCS	0.14	0.09	0.764																	
Ashworth hip adductors	1.2	0.9	0.307																	
ROM hip abductors	5.4	4.8	0.825																	

<p>Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG, electrophysiological guidance; GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP, intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy</p>																																																																
Study details	Key efficacy findings		Key safety findings	Comments																																																												
<p>Mäenpää H (2002)^b</p> <p>Non-randomised comparative study</p> <p>Finland</p> <p>Recruitment period: 1991–1998</p> <p>Study population: children with spastic CP.</p> <p>n = 42 (21 vs 21)</p> <p>Age: both groups: 6 years (mean)</p> <p>Sex: SPR + PT group: 76.2% (16/21); PT-only group: 71.4% (15/21)</p> <p>Patient selection criteria:</p> <p>SPR + PT group: functionally disruptive spasticity in lower limbs (diplegia), 6 months' arrest of motor development or spasticity-dependent difficulties in daily care (quadriplegia).</p> <p>PT-only group: ongoing motor development hypotony or severe weakness of trunk or lower limb muscles; or muscle contractures or rigidity.</p> <p>Technique: SPR + PT (bipolar constant current stimulation used to grade a reflex response as either normal or pathological and rootlets were cut according to the response) vs PT only.</p> <p>Follow-up: 5 years</p> <p>Conflict of interest/source of funding: not reported</p>	<p>Number of patients analysed: 42 (21 vs 21)</p> <p>SPR + PT group: Modified Ashworth Scale score</p> <table border="1"> <thead> <tr> <th>Muscle groups</th><th>Preop</th><th>Postop 1 year</th><th>Postop 3 years</th><th>Postop 5 years</th></tr> </thead> <tbody> <tr> <td>Hip flexors</td><td>4.2</td><td>2.4*</td><td>2.9*</td><td>3.1*</td></tr> <tr> <td>Hip rotators</td><td>4.3</td><td>2.0*</td><td>2.6*</td><td>2.9*</td></tr> <tr> <td>Hip adductors</td><td>4.05</td><td>2.2*</td><td>3.6*</td><td>3.8**</td></tr> <tr> <td>Knee flexors</td><td>4.15</td><td>2.0*</td><td>3.2*</td><td>3.4*</td></tr> <tr> <td>Plantar flexors</td><td>4.3</td><td>2.3*</td><td>2.8*</td><td>2.8*</td></tr> </tbody> </table> <p>*p < 0.05 compared with preoperatively **p < 0.05 compared with 1 year postoperatively</p> <table border="1"> <thead> <tr> <th></th><th>Follow-up</th><th>Mean functional skills (Illinois-St Louis score)</th><th>GMFCS</th></tr> </thead> <tbody> <tr> <td rowspan="4">SPR + PT</td><td>Preop (n = 21)</td><td>6.71 ± 1.62</td><td>3.8 ± 0.7</td></tr> <tr> <td>1 year (n = 21)</td><td>5.86 ± 2.05</td><td>3.47 ± 0.68</td></tr> <tr> <td>3 years (n = 21)</td><td>5.57 ± 2.35</td><td>3.52 ± 0.69</td></tr> <tr> <td>5 years (n = 19)</td><td>5.24* ± 2.83</td><td>3.57 ± 0.76</td></tr> <tr> <td rowspan="4">PT only</td><td>Baseline (n = 21)</td><td>6.66 ± 1.97</td><td>3.42 ± 0.57</td></tr> <tr> <td>1 year (n = 21)</td><td>5.76 ± 2.03</td><td>3.41 ± 0.77</td></tr> <tr> <td>3 years (n = 21)</td><td>5.33* ± 2.58</td><td>3.24 ± 0.78</td></tr> <tr> <td>5 years (n = 19)</td><td>5.4* ± 2.51</td><td>3.25 ± 0.98</td></tr> </tbody> </table> <p>*Significant change compared with preoperatively or baseline.</p>		Muscle groups	Preop	Postop 1 year	Postop 3 years	Postop 5 years	Hip flexors	4.2	2.4*	2.9*	3.1*	Hip rotators	4.3	2.0*	2.6*	2.9*	Hip adductors	4.05	2.2*	3.6*	3.8**	Knee flexors	4.15	2.0*	3.2*	3.4*	Plantar flexors	4.3	2.3*	2.8*	2.8*		Follow-up	Mean functional skills (Illinois-St Louis score)	GMFCS	SPR + PT	Preop (n = 21)	6.71 ± 1.62	3.8 ± 0.7	1 year (n = 21)	5.86 ± 2.05	3.47 ± 0.68	3 years (n = 21)	5.57 ± 2.35	3.52 ± 0.69	5 years (n = 19)	5.24* ± 2.83	3.57 ± 0.76	PT only	Baseline (n = 21)	6.66 ± 1.97	3.42 ± 0.57	1 year (n = 21)	5.76 ± 2.03	3.41 ± 0.77	3 years (n = 21)	5.33* ± 2.58	3.24 ± 0.78	5 years (n = 19)	5.4* ± 2.51	3.25 ± 0.98	<p>SPR + PT group: transient pain due to hyperesthesia: 19% (4/21)</p> <p>Incontinence: 4.8% (1/21)</p> <p>Timing and treatment of complications not reported</p>	<p>Reported in Appendix A in original overview</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> 9.5% (2/21) of patients in both groups lost to follow-up between 3 and 5 years. <p>Study design issues:</p> <ul style="list-style-type: none"> Prospective study. Different selection criteria for treatment groups. Unclear if outcome assessors blinded to treatment allocation. Functional skills assessed using Illinois-St Louis score. Lower scores indicate better functioning. Spasticity not measured in PT-only group. The post-surgical physiotherapy care was not standardised between the groups. <p>Study population issues:</p> <ul style="list-style-type: none"> No statistically significant difference between groups in terms of age, sex, spasticity of lower limbs, numbers with diplegia/quadriplegia, mean Illinois-St Louis scale and mean GMFCS at baseline. Mean proportion of dorsal nerve rootlets sectioned in the SDR group: 44.8%
Muscle groups	Preop	Postop 1 year	Postop 3 years	Postop 5 years																																																												
Hip flexors	4.2	2.4*	2.9*	3.1*																																																												
Hip rotators	4.3	2.0*	2.6*	2.9*																																																												
Hip adductors	4.05	2.2*	3.6*	3.8**																																																												
Knee flexors	4.15	2.0*	3.2*	3.4*																																																												
Plantar flexors	4.3	2.3*	2.8*	2.8*																																																												
	Follow-up	Mean functional skills (Illinois-St Louis score)	GMFCS																																																													
SPR + PT	Preop (n = 21)	6.71 ± 1.62	3.8 ± 0.7																																																													
	1 year (n = 21)	5.86 ± 2.05	3.47 ± 0.68																																																													
	3 years (n = 21)	5.57 ± 2.35	3.52 ± 0.69																																																													
	5 years (n = 19)	5.24* ± 2.83	3.57 ± 0.76																																																													
PT only	Baseline (n = 21)	6.66 ± 1.97	3.42 ± 0.57																																																													
	1 year (n = 21)	5.76 ± 2.03	3.41 ± 0.77																																																													
	3 years (n = 21)	5.33* ± 2.58	3.24 ± 0.78																																																													
	5 years (n = 19)	5.4* ± 2.51	3.25 ± 0.98																																																													

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PEDI, Pediatric Evaluation of Disability Inventory; PT, physical therapy; RCT, randomised controlled trial; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments																																																
<p>Buckon C E (2004)⁷</p> <p>Non-randomised controlled trial</p> <p>USA</p> <p>Recruitment period: over 3 years (dates not reported)</p> <p>Study population: children with spastic diplegia</p> <p>n = 25 (18 vs 7)</p> <p>Age: SDR group: 71.3 months (mean); orthopaedic surgery group: 78.6 months (mean)</p> <p>Sex: 76% (19/25) male</p> <p>Patient selection criteria: children found by an MDT to be appropriate for SDR or orthopaedic soft tissue procedures. SDR patients had to be aged between 4 and 10 years, predominantly spastic, have good trunk control, history of prematurity, no significant ataxia or athetosis, good lower extremity antigravity strength, no significant scoliosis, ambulatory with or without assistive devices, cooperative, ability to isolate lower extremity movements and lower extremity contracture < 10°.</p> <p>Technique: SDR (at L2, 30–50% rootlets were sectioned without electrical stimulation and from L3 to S1 selective electrical stimulation of each nerve rootlet was performed before decision to section) vs aponeurotomy/tenotomy with post-surgical physiotherapy in both groups. Parents chose the treatment therapy after discussions with clinicians.</p> <p>Follow-up: 2 years</p> <p>Conflict of interest/source of funding: no commercial party conferred a benefit on the author.</p>	<p>Number of patients analysed: 25 (18 vs 7)</p> <table border="1"> <thead> <tr> <th></th> <th>SDR baseline (n = 18)</th> <th>SDR 2 years</th> <th>p value</th> <th>Ortho surgery baseline (n = 7)</th> <th>Ortho surgery 2 years</th> <th>p value</th> <th>Between-group p value</th> </tr> </thead> <tbody> <tr> <td>GMPM total</td> <td>54.6 ± 7.0</td> <td>63.4 ± 7.2</td> <td>< 0.001</td> <td>54.1 ± 7.8</td> <td>60.7 ± 9.4</td> <td>< 0.061</td> <td>0.751</td> </tr> <tr> <td>GMFM total</td> <td>82.1 ± 13.2</td> <td>89.5 ± 11.1</td> <td>0.011</td> <td>78.2 ± 13.0</td> <td>85.7 ± 7.1</td> <td>0.048</td> <td>0.540</td> </tr> <tr> <td>Self-care*</td> <td>73.7 ± 13.1</td> <td>84.1 ± 14.2</td> <td>< 0.001</td> <td>75.2 ± 12.7</td> <td>83.4 ± 14.2</td> <td>< 0.014</td> <td>0.932</td> </tr> <tr> <td>Mobility*</td> <td>70.5 ± 10.1</td> <td>77.8 ± 10.4</td> <td>< 0.001</td> <td>69.3 ± 12.6</td> <td>76.7 ± 16.1</td> <td>< 0.042</td> <td>0.511</td> </tr> <tr> <td>Social skills*</td> <td>69.2 ± 8.8</td> <td>75.0 ± 7.9</td> <td>< 0.0004</td> <td>67.5 ± 6.9</td> <td>75.1 ± 11.6</td> <td>< 0.006</td> <td>0.905</td> </tr> </tbody> </table> <p>*Measured using the PEDI.</p>		SDR baseline (n = 18)	SDR 2 years	p value	Ortho surgery baseline (n = 7)	Ortho surgery 2 years	p value	Between-group p value	GMPM total	54.6 ± 7.0	63.4 ± 7.2	< 0.001	54.1 ± 7.8	60.7 ± 9.4	< 0.061	0.751	GMFM total	82.1 ± 13.2	89.5 ± 11.1	0.011	78.2 ± 13.0	85.7 ± 7.1	0.048	0.540	Self-care*	73.7 ± 13.1	84.1 ± 14.2	< 0.001	75.2 ± 12.7	83.4 ± 14.2	< 0.014	0.932	Mobility*	70.5 ± 10.1	77.8 ± 10.4	< 0.001	69.3 ± 12.6	76.7 ± 16.1	< 0.042	0.511	Social skills*	69.2 ± 8.8	75.0 ± 7.9	< 0.0004	67.5 ± 6.9	75.1 ± 11.6	< 0.006	0.905	<p>No safety data was presented in the study report</p>	<p>Reported in table 2 in the original overview</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> • Completeness of follow-up not reported. <p>Study design issues:</p> <ul style="list-style-type: none"> • Prospective study. • The post-surgical physiotherapy care was not standardised between the groups as it was focused to the remedial need, and may have influenced outcome. • All outcomes were evaluated by two investigators who were trained in using the scales. Assessors were not blinded to treatment allocation. <p>Study population issues:</p> <ul style="list-style-type: none"> • Ambulatory = 92% • There were no significant differences between groups at baseline in any of the clinical outcomes measured. • Mean proportion of dorsal nerve rootlets sectioned in the SDR group: 43.3% [calculated by IP analyst]
	SDR baseline (n = 18)	SDR 2 years	p value	Ortho surgery baseline (n = 7)	Ortho surgery 2 years	p value	Between-group p value																																												
GMPM total	54.6 ± 7.0	63.4 ± 7.2	< 0.001	54.1 ± 7.8	60.7 ± 9.4	< 0.061	0.751																																												
GMFM total	82.1 ± 13.2	89.5 ± 11.1	0.011	78.2 ± 13.0	85.7 ± 7.1	0.048	0.540																																												
Self-care*	73.7 ± 13.1	84.1 ± 14.2	< 0.001	75.2 ± 12.7	83.4 ± 14.2	< 0.014	0.932																																												
Mobility*	70.5 ± 10.1	77.8 ± 10.4	< 0.001	69.3 ± 12.6	76.7 ± 16.1	< 0.042	0.511																																												
Social skills*	69.2 ± 8.8	75.0 ± 7.9	< 0.0004	67.5 ± 6.9	75.1 ± 11.6	< 0.006	0.905																																												

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments																																												
<p>Kim D-S (2001)⁸</p> <p>Case series</p> <p>South Korea</p> <p>Recruitment period: 1990–1999</p> <p>Study population: selected patients meeting criteria for posterior rhizotomy.</p> <p>n = 208 (198 patients with spastic CP)</p> <p>Age: 5.9 years (mean)</p> <p>Sex: not reported</p> <p>Patient selection criteria: Spastic diplegia or quadriplegia with CP, spastic hemiplegia of cerebrovascular cause, or spastic quadripareisis due to incomplete spinal cord.</p> <p>Technique: SPR. Access either by laminectomy or later in the cohort by laminoplasty. Posterior nerve root cut into three or four and stimulated, with 50 to 70% of abnormal rootlets cut. Procedure repeated from S2 to L2 and at L1 50% of the bilateral root cut without testing.</p> <p>Follow-up: 4.2 years (mean)</p> <p>Conflict of interest/source of funding: not stated</p>	<p>Number of patients analysed: 208</p> <p>Ability to walk</p> <p>Patients showed an improvement in gait quality (Peacock grading) from 4.2 points at baseline to 5.19 points at 1 year ($p < 0.001$). 81.3% (169/208) of patients showed improvements in ambulatory function.</p> <p>Muscle tone</p> <p>As measured by the Modified Ashworth Scale (mean and standard deviation).</p> <table border="1"> <thead> <tr> <th></th> <th>Baseline (n = 208)</th> <th>1 year (n = 208)</th> <th>4 years (n = 132)</th> </tr> </thead> <tbody> <tr> <td>Hip adductors</td> <td>2.9 ± 1.45</td> <td>0.4 ± 0.72</td> <td>0.4 ± 0.84</td> </tr> <tr> <td>Hamstrings</td> <td>3.2 ± 1.32</td> <td>0.2 ± 0.39</td> <td>0.2 ± 0.53</td> </tr> <tr> <td>Quadriceps</td> <td>2.4 ± 1.05</td> <td>0.5 ± 0.69</td> <td>0.6 ± 0.53</td> </tr> <tr> <td>Gastrocnemius</td> <td>3.6 ± 0.77</td> <td>0.4 ± 0.55</td> <td>0.7 ± 0.51</td> </tr> <tr> <td>Clonus</td> <td>0.8 ± 0.25</td> <td>0.07 ± 0.21</td> <td>0.15 ± 0.29</td> </tr> </tbody> </table> <p>Significant improvements in the spasticity of all tested muscles were noted at 1 and 4 years.</p> <p>There was no statistically significant difference in results between the hemiplegic and diplegic groups.</p> <p>50% (37/74) of patients with arm spasticity showed milder symptoms at the upper extremity after SDR.</p> <p>ROM: changes in passive ROM in degrees</p> <table border="1"> <thead> <tr> <th></th> <th>Baseline (n = 208)</th> <th>1 year (n = 208)</th> <th>4 years (n = 132)</th> </tr> </thead> <tbody> <tr> <td>Flexion contracture of the hips</td> <td>-10.5 ± 12.23</td> <td>-3.3 ± 5.26</td> <td>-4.6 ± 6.33</td> </tr> <tr> <td>Abduction of the hips</td> <td>37.5 ± 16.44</td> <td>59.5 ± 17.56</td> <td>62.5 ± 15.56</td> </tr> <tr> <td>Popliteal angle of the knee</td> <td>-31.7 ± 15.23</td> <td>-27.5 ± 14.25</td> <td>-27.9 ± 13.75</td> </tr> <tr> <td>Dorsiflexion of the ankle</td> <td>-1.3 ± 7.76</td> <td>5 ± 6.76</td> <td>4.8 ± 5.95</td> </tr> </tbody> </table> <p>All patients showed an overall improvement (over 95%) in the range of abduction of the hips and dorsiflexion of the ankles, a decrease in the flexional contracture of the hips, and more normal popliteal angles.</p>		Baseline (n = 208)	1 year (n = 208)	4 years (n = 132)	Hip adductors	2.9 ± 1.45	0.4 ± 0.72	0.4 ± 0.84	Hamstrings	3.2 ± 1.32	0.2 ± 0.39	0.2 ± 0.53	Quadriceps	2.4 ± 1.05	0.5 ± 0.69	0.6 ± 0.53	Gastrocnemius	3.6 ± 0.77	0.4 ± 0.55	0.7 ± 0.51	Clonus	0.8 ± 0.25	0.07 ± 0.21	0.15 ± 0.29		Baseline (n = 208)	1 year (n = 208)	4 years (n = 132)	Flexion contracture of the hips	-10.5 ± 12.23	-3.3 ± 5.26	-4.6 ± 6.33	Abduction of the hips	37.5 ± 16.44	59.5 ± 17.56	62.5 ± 15.56	Popliteal angle of the knee	-31.7 ± 15.23	-27.5 ± 14.25	-27.9 ± 13.75	Dorsiflexion of the ankle	-1.3 ± 7.76	5 ± 6.76	4.8 ± 5.95	<p>Complications</p> <ul style="list-style-type: none"> Back pain: experienced by all patients but well controlled by intravenous fentanyl for 3 days in most patients. 3.4% (7/208) had long-standing back pain at final follow-up. Postoperative spinal deformity (radiographic findings only and no functional findings, relating to excessive laminectomy): 6% (12/208). Scoliosis (radiologically observed): 9% (5/58) of patients who had laminectomy, and 1.3% (2/150) who had laminoplasty. Hypotonia: most SDR patients had temporary hypotonia following the surgery but this resolved over 2 to 3 months of scheduled physical therapy for most, although 3% (7/208) still had hypotonia at final follow-up. Urinary retention because of decreased bladder tone and hyporeflexia: 9.6% (20/208). This resolved spontaneously within 4 weeks in 18 patients, but 2 patients had long-term incontinence due to atonic bladder. This was effectively treated with clean intermittent catheterisation in 1 patient. Transient sensory changes: 7% (15/208); 5 of these patients had sensory changes to final follow-up but these were not functionally important. Aspiration pneumonia: 1% (2/208). Involuntary arm movement: 1% (2/208). 2 patients required orthopaedic surgery for progressive hip migration. 	<p>Reported in table 2 in the original overview</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> 36.5% (76/208) lost to follow-up between 1 and 4 years. <p>Study design issues:</p> <ul style="list-style-type: none"> Retrospective study. No value for degree of certainty of statistical results are given for most outcomes. Postoperative physiotherapy regimen (if any) is not described. <p>Study population issues:</p> <ul style="list-style-type: none"> Study includes 8 patients with spastic hemiplegia after cerebrovascular insult and 2 patients with spastic quadripareisis after cervical cord injury. The percentage of patients with scoliosis preoperatively was not reported <p>Other issues:</p> <ul style="list-style-type: none"> Authors state that other causes other than spasticity can influence child ambulation. Long-standing spasticity in older children resulted in more severe musculoskeletal contracture, which was more difficult to correct with SDR.
	Baseline (n = 208)	1 year (n = 208)	4 years (n = 132)																																												
Hip adductors	2.9 ± 1.45	0.4 ± 0.72	0.4 ± 0.84																																												
Hamstrings	3.2 ± 1.32	0.2 ± 0.39	0.2 ± 0.53																																												
Quadriceps	2.4 ± 1.05	0.5 ± 0.69	0.6 ± 0.53																																												
Gastrocnemius	3.6 ± 0.77	0.4 ± 0.55	0.7 ± 0.51																																												
Clonus	0.8 ± 0.25	0.07 ± 0.21	0.15 ± 0.29																																												
	Baseline (n = 208)	1 year (n = 208)	4 years (n = 132)																																												
Flexion contracture of the hips	-10.5 ± 12.23	-3.3 ± 5.26	-4.6 ± 6.33																																												
Abduction of the hips	37.5 ± 16.44	59.5 ± 17.56	62.5 ± 15.56																																												
Popliteal angle of the knee	-31.7 ± 15.23	-27.5 ± 14.25	-27.9 ± 13.75																																												
Dorsiflexion of the ankle	-1.3 ± 7.76	5 ± 6.76	4.8 ± 5.95																																												

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments																														
<p>Steinbok P (2005)⁹</p> <p>Case series</p> <p>Canada</p> <p>Recruitment period: 1987 - 2001</p> <p>Study population: children < 18years with spastic cerebral palsy in whom pr- and post-operative spine radiographs were available</p> <p>n = 105</p> <p>Age: 5.2 years (mean)</p> <p>Sex: 53.3% (56/105) male</p> <p>Patient selection criteria: see above</p> <p>Technique: SDR (via multilevel laminectomies or laminoplasties, usually from L1 to S1 with 20-90% of dorsal roots cut.</p> <p>Electrophysiology used during the procedure)</p> <p>Follow-up: 4.3 years (mean)</p> <p>Conflict of interest/source of funding: not reported</p>	Not reported	<p>Scoliosis (n=104)</p> <table border="1"> <thead> <tr> <th></th> <th>Preop</th> <th>Follow-up</th> </tr> </thead> <tbody> <tr> <td>Mean Cobb angle for scoliosis (standard deviation)</td> <td>6.6° (6.2°)</td> <td>12.5° (15°)</td> </tr> <tr> <td>% with scoliosis ≥ 10°</td> <td>-</td> <td>54.8% (57/104)</td> </tr> <tr> <td>% with scoliosis ≥35°</td> <td>-</td> <td>5.8% (6/104)</td> </tr> </tbody> </table> <p>1 patient underwent spinal fusion to correct scoliosis and 1 patient underwent fusion to correct lordoscoliosis.</p> <p>Kyphosis (n=44)</p> <table border="1"> <thead> <tr> <th></th> <th>Preop</th> <th>Follow-up</th> </tr> </thead> <tbody> <tr> <td>Mean Cobb angle for kyphosis (standard deviation)</td> <td>34.8° (13.3°)</td> <td>38.2° (13°)</td> </tr> <tr> <td>% with kyphosis ≥39.5°</td> <td>-</td> <td>40.9% (18/44)</td> </tr> </tbody> </table> <p>Lordosis (n=47)</p> <table border="1"> <thead> <tr> <th></th> <th>Preop</th> <th>Follow-up</th> </tr> </thead> <tbody> <tr> <td>Mean Cobb angle for lordosis (standard deviation)</td> <td>30.8° (13.5°)</td> <td>41.2° (15.2°)</td> </tr> <tr> <td>% with lordosis >54°</td> <td>-</td> <td>21.3% (10/47)</td> </tr> </tbody> </table>		Preop	Follow-up	Mean Cobb angle for scoliosis (standard deviation)	6.6° (6.2°)	12.5° (15°)	% with scoliosis ≥ 10°	-	54.8% (57/104)	% with scoliosis ≥35°	-	5.8% (6/104)		Preop	Follow-up	Mean Cobb angle for kyphosis (standard deviation)	34.8° (13.3°)	38.2° (13°)	% with kyphosis ≥39.5°	-	40.9% (18/44)		Preop	Follow-up	Mean Cobb angle for lordosis (standard deviation)	30.8° (13.5°)	41.2° (15.2°)	% with lordosis >54°	-	21.3% (10/47)	<p>Reported in Appendix A in the original overview</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> Preoperative anteroposterior radiograph not available for one patient. <p>Study design issues:</p> <ul style="list-style-type: none"> Retrospective study. Postoperative physiotherapy regimen (if any) is not described. <p>Study population issues:</p> <ul style="list-style-type: none"> 59% (62/105) patients had spastic diplegia, 32.4% (34/105) had spastic quadriplegia and 8.6% (9/105) had quadriplegia and intellectual delay. Preoperative ambulatory status: 25.7% (27/105) used a wheelchair, 19% (20/105) could commando crawl, 17.1% (18/105) 4 point crawling, 23.8% (25/105) walked using a walker, 1.9% (2/105) used crutches and 12.4% (13/105) walked independently.
	Preop	Follow-up																															
Mean Cobb angle for scoliosis (standard deviation)	6.6° (6.2°)	12.5° (15°)																															
% with scoliosis ≥ 10°	-	54.8% (57/104)																															
% with scoliosis ≥35°	-	5.8% (6/104)																															
	Preop	Follow-up																															
Mean Cobb angle for kyphosis (standard deviation)	34.8° (13.3°)	38.2° (13°)																															
% with kyphosis ≥39.5°	-	40.9% (18/44)																															
	Preop	Follow-up																															
Mean Cobb angle for lordosis (standard deviation)	30.8° (13.5°)	41.2° (15.2°)																															
% with lordosis >54°	-	21.3% (10/47)																															

<p>Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG, electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, gross motor performance measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy</p>			
Study details	Key efficacy findings	Key safety findings	Comments

Golan JD (2007)¹⁰

Case series

Canada

Recruitment period: 1991–2001
Study population: children with spastic cerebral palsy

n = 98

Age: 5.1 years (mean)
Sex: 61.2% (60/98) male

Patient selection criteria: all patients who underwent SDR, had pre- and post-operative radiographic spinal studies and a minimum of 1 year follow-up were included.

Technique: SDR (multilevel L1 to S1 laminectomy with mean 53.8% rootlets cut) followed by 6 weeks of intensified inpatient rehabilitation.

Follow-up: 5.8 years (mean)

Conflict of interest/source of funding: not reported

Key efficacy findings

Not reported

Key safety findings

Scoliosis

Mild scoliosis in patients with post-operative weight bearing radiograph: 42.8% (39/87)

For patients with pre- and post-operative weight bearing radiographs (n=35):

	Preoperative	Follow-up
Mean Cobb angle	6.4°	8.3°
% scoliosis ≥10°	31.4% (11/35)	42.9% (15/35)

Of the 15 cases at follow-up, 6 cases had improved by ≥10° and 9 had worsened by ≥10° in comparison to the preoperative radiograph.

Thoracic kyphosis (requires standing radiograph to confirm):

	Preoperative (n=10)	Follow-up (n=50)
% kyphosis exceeding upper limit of normal	20% (2/10)	12% (6/50)

Lumbar lordosis (requires standing radiograph to confirm):

	Preoperative (n=17)	Follow-up (n=53)
Mean lordotic angle	-34.2°	-47.7°
% curve exceeds upper limit of normal	5.9% (1/17)	32.1% (17/53)

Spondylolisthesis: 19.1% (18/94) at follow-up

Comments

Follow-up issues:

- 4.1% (4/98) did not have postoperative radiographs
- 11.2% (11/98) did not have postoperative weight bearing radiographs.
- 64.3% (68/98) did not have pre- and post-operative weight-bearing radiographs.

Study design issues:

- Retrospective study.
- Clinically significant deformity defined as scoliosis > 25° or a sagittal plane exceeding the normal limit, including spondylolisthesis, with associated back pain or radiculopathy.

Study population issues:

- Preoperative ambulatory status: walking independently: 32.7% (32/98), walking with mobility aids: 53.1% (52/98), 4 point crawlers: 9.2% (9/98) and commando crawlers: 5.1% (5/98)

Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, Gross Motor Performance Measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy

Study details	Key efficacy findings	Key safety findings	Comments												
<p>Li Z (2008)¹¹</p> <p>Case series</p> <p>China</p> <p>Recruitment period: 1992–2002</p> <p>Study population: subset of patients with spastic CP who underwent SDR and had follow-up lumbar spine radiographs in 2004/5</p> <p>n = 61 Age: 6.9 years (mean) Sex: data are unclear</p> <p>Patient selection criteria: unclear</p> <p>Technique: SDR (selection of rootlets sectioned based on electrophysiology response to intraoperative electrical stimulation)</p> <p>Follow-up: 6.3 years (mean)</p> <p>Conflict of interest/source of funding: not reported</p>	<p>Not reported</p>	<p><u>Lumbar spine radiographs</u></p> <table border="1" data-bbox="747 372 1381 654"> <thead> <tr> <th></th> <th>Preop</th> <th>Follow-up</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>Mean angle of hyperlordosis</td> <td>17.9° ± 4.5°</td> <td>29.3° ± 4.6°</td> <td>< 0.05</td> </tr> <tr> <td>Lumbar hyperlordosis</td> <td>1.6% (1/61)</td> <td>16.4% (10/61) [knee hyperextension in 3 cases]</td> <td>Not reported</td> </tr> </tbody> </table> <p>Of the 10 patients with lumbar hyperlordosis after SDR who all showed distinctively abnormal walking posture, 4 patients developed spondylolysis and grade-I spondylolisthesis at 3, 4 and 5 years after the procedure. One patient developed lumbar kyphosis deformity 7 years after surgery.</p> <p>In addition, one case of scoliosis and two cases of L₅ spondylolysis were detected before the procedure.</p>		Preop	Follow-up	p value	Mean angle of hyperlordosis	17.9° ± 4.5°	29.3° ± 4.6°	< 0.05	Lumbar hyperlordosis	1.6% (1/61)	16.4% (10/61) [knee hyperextension in 3 cases]	Not reported	<p>Follow-up issues:</p> <ul style="list-style-type: none"> 219 patients treated during recruitment period. It is unclear why only 27.9% (61/219) had postoperative lumbar spine radiographs or how these patients were selected. <p>Study design issues:</p> <ul style="list-style-type: none"> Retrospective study <p>Study population issues:</p> <ul style="list-style-type: none"> Percentage of dorsal nerve rootlets sectioned in the SDR group was not reported.
	Preop	Follow-up	p value												
Mean angle of hyperlordosis	17.9° ± 4.5°	29.3° ± 4.6°	< 0.05												
Lumbar hyperlordosis	1.6% (1/61)	16.4% (10/61) [knee hyperextension in 3 cases]	Not reported												

<p>Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG, electrophysiological guidance; GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, Gross Motor Performance Measure; ITBP, intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy</p>																																			
Study details	Key efficacy findings	Key safety findings	Comments																																
<p>Langerak NG (2009a)¹²</p> <p>Case series</p> <p>South Africa</p> <p>Recruitment period: SDR procedure: 1981–1991, follow-up: 2008</p> <p>Study population: patients with spastic CP.</p> <p>n = 30</p> <p>Age: at SDR procedure: 5.2 years (median), at follow-up: 26.8 years (median)</p> <p>Sex: 56.7% (17/30) male</p> <p>Patient selection criteria: inclusion: diagnosis of cerebral palsy with spasticity mainly with involvement of lower limbs, ambulant before 4 years of age, goal of SDR is functional improvement and improvement gait pattern. Patients had to have lived within 100km of Cape Town when they had the procedure to be included in this study. Exclusion: dystonic, athetotic, ataxia or hypotonic cerebral palsy, diagnosis of other neuromuscular disorders.</p> <p>Technique: SDR</p> <p>Follow-up: 21.4 years (median)</p> <p>Conflict of interest/source of funding: none</p>	<p>Long term follow-up:</p> <p>ODI (N=30)</p> <p>Minimal disability due to back pain (score 0–20%): 76.7% (23/30)</p> <p>Moderate disability due to back pain (score 20–40%): 23.3% (7/30)</p> <p>Other pain scores</p> <p>3–10% of patients reported pain in their upper extremities</p> <p>23–4% of patients reported pain in their lower extremities.</p> <p>20% reported pain at the cervical spinal level</p> <p>67% reported pain at the lumbosacral level.</p>	<table border="1"> <thead> <tr> <th></th><th>% with scoliosis</th></tr> </thead> <tbody> <tr> <td>Short-term follow-up (median 4 years)[n=28]</td><td>0%</td></tr> <tr> <td>Long-term follow-up (median 21.4 years) [n=30]</td><td>Curve <35°: 50% (15/30) Curve 35°: 6.7% (2/30)</td></tr> <tr> <td>p value</td><td><0.01</td></tr> </tbody> </table> <table border="1"> <thead> <tr> <th></th><th>% with kyphosis</th></tr> </thead> <tbody> <tr> <td>Short-term follow-up (median 4 years)[n=28]</td><td>0</td></tr> <tr> <td>Long-term follow-up (median 21.4 years) [n=30]</td><td>6.7% (2/30)</td></tr> <tr> <td>p value</td><td>0.32</td></tr> </tbody> </table> <table border="1"> <thead> <tr> <th></th><th>% with lordosis</th></tr> </thead> <tbody> <tr> <td>Short-term follow-up (median 4 years)[n=28]</td><td>20% (6/30)</td></tr> <tr> <td>Long-term follow-up (median 21.4 years) [n=30]</td><td>40% (12/30)</td></tr> <tr> <td>p value</td><td>0.13</td></tr> </tbody> </table> <table border="1"> <thead> <tr> <th></th><th>% with spondylolysis</th></tr> </thead> <tbody> <tr> <td>Short-term follow-up (median 4 years)[n=28]</td><td>16.7% (5/30)</td></tr> <tr> <td>Long-term follow-up (median 21.4 years) [n=30]</td><td>36.7% (11/30)</td></tr> <tr> <td>p value</td><td>0.13</td></tr> </tbody> </table>		% with scoliosis	Short-term follow-up (median 4 years)[n=28]	0%	Long-term follow-up (median 21.4 years) [n=30]	Curve <35°: 50% (15/30) Curve 35°: 6.7% (2/30)	p value	<0.01		% with kyphosis	Short-term follow-up (median 4 years)[n=28]	0	Long-term follow-up (median 21.4 years) [n=30]	6.7% (2/30)	p value	0.32		% with lordosis	Short-term follow-up (median 4 years)[n=28]	20% (6/30)	Long-term follow-up (median 21.4 years) [n=30]	40% (12/30)	p value	0.13		% with spondylolysis	Short-term follow-up (median 4 years)[n=28]	16.7% (5/30)	Long-term follow-up (median 21.4 years) [n=30]	36.7% (11/30)	p value	0.13	<p>Follow-up issues:</p> <ul style="list-style-type: none"> 47 eligible patients, of whom 78.7% (37/47) were tracked down by the researchers. Of these, 81.1% (30/37) agreed to take part in the study. 6.7% (2/30) patients did not participate in the short-term follow-up. <p>Study design issues:</p> <ul style="list-style-type: none"> Retrospective study Patients had X-rays at short-term follow-up. Patients had X-ray and MRI scans of the spine at long-term follow-up in 2008. Unclear whether assessment was made by independent reviewers. <p>Study population issues:</p> <ul style="list-style-type: none"> Position of laminectomies: 70% L1/2 to S1, 10% L1 to L5, 10% L2 to L5, 3% L2 to S2 and 7% L3 to S1. All patients ambulant at follow-up. 66.7% (20/30) walked without walking aids, 13.3% (4/30) used 1 or 2 crutches when outdoors only and 20% (6/30) always used crutches. Before SDR 48% had muscle releasing surgical procedures and 10% had osteotomies of the femur or foot/toes. After SDR, 60% (18/30) had a surgical procedure: 59% had muscle releasing procedures and 31% had osteotomies.
	% with scoliosis																																		
Short-term follow-up (median 4 years)[n=28]	0%																																		
Long-term follow-up (median 21.4 years) [n=30]	Curve <35°: 50% (15/30) Curve 35°: 6.7% (2/30)																																		
p value	<0.01																																		
	% with kyphosis																																		
Short-term follow-up (median 4 years)[n=28]	0																																		
Long-term follow-up (median 21.4 years) [n=30]	6.7% (2/30)																																		
p value	0.32																																		
	% with lordosis																																		
Short-term follow-up (median 4 years)[n=28]	20% (6/30)																																		
Long-term follow-up (median 21.4 years) [n=30]	40% (12/30)																																		
p value	0.13																																		
	% with spondylolysis																																		
Short-term follow-up (median 4 years)[n=28]	16.7% (5/30)																																		
Long-term follow-up (median 21.4 years) [n=30]	36.7% (11/30)																																		
p value	0.13																																		

<p>Abbreviations used: BTA, botulinum toxin type A; CP, cerebral palsy; EPG; electrophysiological guidance; GMFCS; Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; GMPM, Gross Motor Performance Measure; ITBP; intrathecal baclofen pumps; MDT, multidisciplinary team; PT, physical therapy; RCT, randomised controlled trials; ROM, range of motion; SDR, selective dorsal rhizotomy; SPR, selective posterior rhizotomy</p>																																						
Study details	Key efficacy findings	Key safety findings	Comments																																			
<p>Langerak NG (2009b)¹³</p> <p>Case series</p> <p>South Africa</p> <p>Recruitment period: 1985 - 1986</p> <p>Study population: Patients with spastic diplegia of congenital origin</p> <p>n = 14</p> <p>Age: 28 years (mean)</p> <p>Sex: 57.1% (8/14) male</p> <p>Patient selection criteria: patients had to be ambulant preoperatively and have access to intensive physiotherapy before and after surgery.</p> <p>Technique: Selective dorsal rhizotomy</p> <p>Follow-up: 20 years</p> <p>Conflict of interest/source of funding: None</p>	<p>Number of patients analysed: 14</p> <p>GMFCS 71.4% (10/14) improved by 1 level on GMFCS, 21.4% (3/14) remained unchanged and 1 patient deteriorated from level 3 to 5 at 20-year follow-up.</p> <table border="1"> <thead> <tr> <th></th><th>Median pre-op score</th><th>Median 1 year post op score</th><th>Median 20 year post op score</th><th>p value pre-1 yr</th><th>p value pre-20 yr</th><th>p value 1 yr-20 yr</th></tr> </thead> <tbody> <tr> <td>Muscle tone</td><td>3.1</td><td>2.1</td><td>2.0</td><td><0.001</td><td><0.001</td><td>0.859</td></tr> <tr> <td>Joint stiffness</td><td>1.9</td><td>1.2</td><td>1.3</td><td>0.001</td><td>0.019</td><td>0.972</td></tr> <tr> <td>Voluntary movement</td><td>3.6</td><td>2.3</td><td>1.9</td><td>0.001</td><td>0.002</td><td>0.021</td></tr> <tr> <td>Functional movement</td><td>3.1</td><td>1.9</td><td>1.8</td><td><0.001</td><td><0.001</td><td>0.328</td></tr> </tbody> </table> <p>Further orthopaedic surgery 64.3% (9/14) had at least 1 further orthopaedic surgery (achilles' tendon procedure: 2 patients, hamstring procedure: 3 patients and rectus fomoris procedure: 1 patient, foot osteotomy: 6 patients and femur osteotomy: 1 patient). No patients received an intrathecal baclofen pump or botulinum toxin injections. 1 patient used oral antispasmodic medication after SDR.</p> <p>Activities of daily living All patients said they did not need help with daily activities at 20 year follow-up. 78.6% (11/14) were employed or studying.</p>		Median pre-op score	Median 1 year post op score	Median 20 year post op score	p value pre-1 yr	p value pre-20 yr	p value 1 yr-20 yr	Muscle tone	3.1	2.1	2.0	<0.001	<0.001	0.859	Joint stiffness	1.9	1.2	1.3	0.001	0.019	0.972	Voluntary movement	3.6	2.3	1.9	0.001	0.002	0.021	Functional movement	3.1	1.9	1.8	<0.001	<0.001	0.328	<p>Not reported</p>	<p>Overlap with Langerak 2009a</p> <p>Follow-up issues:</p> <ul style="list-style-type: none"> • Complete follow-up for all patients <p>Study design issues:</p> <ul style="list-style-type: none"> • Patients were all treated by the same neurosurgeon at one hospital. • Video of follow-up assessment reviewed by 2 physiotherapists blinded to the 1-year follow-up outcome to confirm final scores. • GMFCS percentages are reported as 64% (n=10) improved by 1 level on GMFCS, 29% (n=3) remained unchanged and 7% (n=1) deteriorated from level 3 to 5 in the papers. Interventional Procedures analyst has assumed the raw data is correct and adjusted the percentages accordingly.
	Median pre-op score	Median 1 year post op score	Median 20 year post op score	p value pre-1 yr	p value pre-20 yr	p value 1 yr-20 yr																																
Muscle tone	3.1	2.1	2.0	<0.001	<0.001	0.859																																
Joint stiffness	1.9	1.2	1.3	0.001	0.019	0.972																																
Voluntary movement	3.6	2.3	1.9	0.001	0.002	0.021																																
Functional movement	3.1	1.9	1.8	<0.001	<0.001	0.328																																

Efficacy

Reduction in spasticity (Modified Ashworth Scale)

A meta-analysis of 3 randomised controlled trials (RCTs) including a total of 90 patients reported a mean change in Modified Ashworth Scale score of -1.23 ($p < 0.01$), indicating a reduction in spasticity following selective dorsal rhizotomy at 9-month follow-up (1 study) and 12-month follow-up (2 studies)¹.

A non-randomised comparative study of 142 patients reported that 71 patients treated by selective dorsal rhizotomy had an improvement in mean Modified Ashworth Scale score of -2.52 compared with -1.23 for 71 patients treated by intrathecal baclofen pumps (ITBP) ($p < 0.0001$) at 1-year follow-up².

A non-randomised study of 44 patients reported that 22 patients treated by selective dorsal rhizotomy using electrophysiological guidance had a similar change in Ashworth hip adductors score from baseline to 1-year follow-up as the 22 patients treated by selective dorsal rhizotomy without using electrophysiological guidance (1.2 vs. 0.9, $p = 0.307$)⁵.

A case series of 208 patients (198 with cerebral palsy) reported a significant improvement in the spasticity of all tested muscles at 1- and 4-year follow-up⁸.

Gross motor function

The meta-analysis reported a mean change in GMFM score of 4.53 ($p = 0.002$), indicating an increase in gross motor function following treatment with selective dorsal rhizotomy. The same study showed that GMFM scores improved by 8% in the selective dorsal rhizotomy plus physical therapy group compared with 4% in the physical therapy-only group ($p = 0.008$) at 9-month follow-up (1 study) and 12-month follow-up (2 studies)¹.

The non-randomised comparative study of 142 patients reported that 71 patients treated by selective dorsal rhizotomy had mean GMFCS scores of -0.66 compared with -0.08 for 71 patients treated by ITBP ($p < 0.0001$) at 1-year follow-up².

A non-randomised comparative study of 108 patients reported that 31 patients treated by selective dorsal rhizotomy had a mean improvement in GMFM score from 87 preoperatively to 92 postoperatively ($p < 0.05$) at 20-month follow-up³.

A non-randomised study of 44 patients reported that 22 patients treated by selective dorsal rhizotomy using electrophysiological guidance had a similar change in GMFCS from baseline to 1-year follow-up as the 22 patients treated by selective dorsal rhizotomy without using electrophysiological guidance (0.14 vs. 0.09, $p = 0.764$)⁵.

A non-randomised comparative study of 42 patients reported no significant change in GMFCS between baseline and 5 years in 21 patients treated by

IP overview: selective dorsal rhizotomy for spasticity in cerebral palsy

selective dorsal rhizotomy (referred to as selective posterior rhizotomy in study) plus physical therapy or in 21 patients treated by physical therapy only⁶.

A non-randomised comparative study of 25 patients reported improvement in mean GMFM from 82.1 at baseline to 89.5 ($p = 0.011$) in 18 patients treated by selective dorsal rhizotomy and 78.2 at baseline to 85.7 ($p = 0.048$) in 7 patients treated by orthopaedic surgery. There was no significant difference in improvement between groups ($p = 0.54$) at 2-year follow-up⁷.

A case series of 14 patients reported that 71% (10/14) improved by 1 level on the GMFCS, 21% (3/14) remained unchanged and 1 patient deteriorated from level 3 to level 5 at 20-year follow-up¹³.

Patient satisfaction

The non-randomised comparative study of 142 patients reported that 94% of 71 patients treated by selective dorsal rhizotomy and 96% of 71 patients treated by ITBP (absolute figures not reported) were satisfied at 1-year follow-up ($p = 0.71$)².

A case series of 14 patients reported that all patients did not need help with daily activities and 79% (11/14) were employed or studying at 20-year follow-up¹³.

Safety

Spinal deformity

The case series of 208 patients reported radiologically observed scoliosis in 9% (5/58) of patients who had laminectomy and 1% (2/150) of patients who had laminoplasty at a mean follow-up of 4.2 years. The percentage of patients with scoliosis preoperatively is not reported⁸.

A case series of 105 patients reported that 55% (57/104) of patients with pre- and postoperative spinal radiographs had scoliosis of 10° or greater at mean 4.3-year follow-up. The same study reported that 21% (10/47) of patients with pre- and postoperative spinal radiographs had lordosis greater than 54° at mean 4.3-year follow-up⁹.

A case series of 98 patients reported scoliosis of 10° or greater (for patients who had both pre- and postoperative weightbearing spinal radiographs) in 31% (11/35) of patients pre-operatively and 43% (15/35) of patients at mean 5.8-year follow-up. The same study reported that 6% (1/17) of patients with a pre-operative standing radiograph and 32% (17/53) with a postoperative standing radiograph had hyperlordosis at mean 5.8-year follow-up¹⁰.

A case series of 61 patients reported an increase in the mean angle of hyperlordosis from 17.9° at baseline to 29.3° at a mean follow-up of 6.3 years

($p < 0.05$). This study reported 10 patients with lumbar hyperlordosis (with distinctively abnormal walking posture) after the procedure (1 patient had this condition at baseline). Four patients developed spondylolysis and grade-I spondylolisthesis at 3, 4 and 5 years after the procedure and 1 patient developed lumbar kyphosis 7 years after the procedure¹¹.

A case series of 30 patients reported a significant increase in the proportion of patients with scoliosis, from 0% at median 4-year follow-up after selective dorsal rhizotomy to 50% (15/30) with a curve of less than 35° and 7% (2/30) with a curve greater than 35° at median 21.4-year follow-up ($p < 0.01$). The same study reported a non-significant increase in the proportion of patients with lordosis, from 20% (6/30) at median 4-year follow-up to 40% (12/30) at median 21.4-year follow-up ($p = 0.13$)¹².

Bladder problems

The non-randomised comparative study of 42 patients reported that 1 patient of 21 treated by selective dorsal rhizotomy (referred to as selective posterior rhizotomy in the study) plus physical therapy had incontinence following the procedure. Timing, duration and treatment for this complication were not reported⁶.

The case series of 208 patients reported urinary retention due to decreased bladder tone and hyporeflexia in 10% (20/208) of patients. This resolved spontaneously within 4 weeks in 18 patients but 2 patients had long-term incontinence due to atonic bladder⁸.

Back pain

The case series of 208 patients reported 3% (7/208) of patients had long-standing back pain at a mean follow-up of 4.2 years⁸.

A case series of 30 patients reported that 23% (7/30) patients had moderate disability due to back pain (ODI score of 20 to 40%) at median 21.4-year follow-up¹².

Validity and generalisability of the studies

- Most of the studies (5 of 8) reported in table 2 appeared in the original overview.
- Different comparator treatments (physical therapy, orthopaedic surgery and ITBP) are used in the available studies.

Existing assessments of this procedure

There were no published assessments from other organisations identified at the time of the literature search.

Related NICE guidance

The Australian Medical Services Advisory Committee published an assessment for nationally funded centre (NFC) status on selective dorsal rhizotomy (SDR) in November 2006. The Committee recommended that:

- one NFC for SDR should be established.
- the cost estimates from the NFC should be reviewed according to the patient referral base.
- a national protocol for the management of patients with SDR should be developed and implemented with agreement between the NFC and referral centres.
- high-quality prospective data with long-term follow-up on all patients treated with SDR and other management options should be collected using a common protocol for data collection to ensure a common dataset across Australia is established. Data collection should allow for monitoring of possible adverse events such as spinal deformity.
- an accelerated review of the number of centres is required in view of the likelihood that this service will diffuse in the future due to the availability of appropriate technical expertise and multidisciplinary spasticity management services and the opportunity to improve patient access¹⁴.

Interventional procedures

- Selective dorsal rhizotomy for spasticity in cerebral palsy. NICE interventional procedures guidance 195 (2006). Available from www.nice.org.uk/guidance/IPG195 (Current guidance)

Specialist Advisers' opinions

Specialist advice was sought from consultants who have been nominated or ratified by their Specialist Society or Royal College. The advice received is their individual opinion and does not represent the view of the society.

Professor MS Eljamel (Society of British Neurosurgical Surgeons), Mr Martin Smith and Mr Richard Edwards (British Paediatric Neurosurgical Group) and Mr Andrew Roberts (British Orthopaedic Association).

- One Specialist Adviser performs the procedure regularly, two have never performed the procedure and the other did not report his level of experience.
- Three Specialist Advisers stated that this is established practice.
- Two Specialist Advisers stated that there is only one UK centre where this procedure is performed. Three other centres have expressed an interest in performing this procedure.
- The comparators are intrathecal baclofen infusion, multi-level orthopaedic surgery and physiotherapy.
- Theoretical adverse events: death, worsening motor function and/or paraplegia, dislocation of the hips, back pain, sensory disturbance, urinary incontinence, constipation, weakness, chronic pain, wound infection, cauda equina, scoliosis, spinal deformity, cerebrospinal fluid leakage, late arachnoiditis and/or syringomyelia and meningitis.
- Efficacy outcomes: reduction in lower limb spasticity, improvement in gross motor function, improved gait and walking, reduction in number of subsequent orthopaedic procedures, level of independence and quality of life.
- Training and facilities: specialised neurosurgical centres and multidisciplinary teams including neurosurgeon, neurologist, paediatric anaesthetist, physiotherapist, spinal neurophysiology monitoring facilities, specialised equipment for surgery and intra-operative management, paediatric rehabilitation facilities and specialist orthotic services. Training should be a specific fellowship in paediatric neurosurgery at a centre undertaking the procedure.
- Two Specialist Advisers highlighted the importance of appropriate case selection (1 pointed out that the procedure is irreversible).
- One Specialist Adviser indicated that long-term follow-up data (5+ years) is required on this procedure.

Patient Commentators' opinions

- NICE's Patient and Public Involvement programme were unable to gather patient commentary for this procedure.

Issues for consideration by IPAC

- A systematic review of 'Selective dorsal rhizotomy in the management of children with spastic cerebral palsy' by the Cochrane Collaboration is currently in development¹⁵.

References

1. McLaughlin J, Bjornson K, Temkin N et al. (2002) Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. *Developmental Medicine & Child Neurology* 44:17-25.
2. Kan P, Gooch J, Amini A et al. (2008) Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation. *Childs Nervous System* 24:239-243.
3. Engsberg JR, Ross SA, Collins DR et al. (2006) Effect of selective dorsal rhizotomy in the treatment of children with cerebral palsy.[see comment]. *Journal of Neurosurgery* 105:Suppl-15.
4. Wong AM, Pei YC, Lui TN et al. (2005) Comparison between botulinum toxin type A injection and selective posterior rhizotomy in improving gait performance in children with cerebral palsy. *Journal of Neurosurgery* 102:385-389.
5. Steinbok P, Tidemann AJ, Miller S et al. (2009) Electrophysiologically guided versus non-electrophysiologically guided selective dorsal rhizotomy for spastic cerebral palsy: a comparison of outcomes. *Childs Nervous System* VOL 25; NUMBER 9:1091-1096.
6. Maenpaa H, Salokorpi T, Jaakkola R et al. (2003) Follow-up of children with cerebral palsy after selective posterior rhizotomy with intensive physiotherapy or physiotherapy alone. *Neuropediatrics* 34:67-71.
7. Buckon CE, Thomas SS, Piatt JH, Jr. et al. (2004) Selective dorsal rhizotomy versus orthopedic surgery: a multidimensional assessment of outcome efficacy. *Archives of Physical Medicine & Rehabilitation* 85:457-465.
8. Kim DS, Choi JU, Yang KH et al. (2001) Selective posterior rhizotomy in children with cerebral palsy: a 10-year experience. *Childs Nervous System* 17:556-562.
9. Steinbok P, Hicdonmez T, Sawatzky B et al. (2005) Spinal deformities after selective dorsal rhizotomy for spastic cerebral palsy. *Journal of Neurosurgery* 102:363-373.
10. Golan JD, Hall JA, O'Gorman G et al. (2007) Spinal deformities following selective dorsal rhizotomy. *Journal of Neurosurgery* 106:Suppl-9.
11. Li Z, Zhu J, and Liu X. (2008) Deformity of lumbar spine after selective dorsal rhizotomy for spastic cerebral palsy. *Microsurgery* 28:10-12.
12. Langerak NG, Vaughan CL, Hoffman EB et al. (2009) Incidence of spinal abnormalities in patients with spastic diplegia 17 to 26 years after selective dorsal rhizotomy. *Childs Nervous System* 25:1593-1603.

13. Langerak NG, Lamberts RP, Fieggen AG et al. (2009) Functional status of patients with cerebral palsy according to the International Classification of Functioning, Disability and Health model: a 20-year follow-up study after selective dorsal rhizotomy. *Archives of Physical Medicine & Rehabilitation* 90:994-1003.
14. Australian Medical Services Advisory Committee. (1-11-2006) Selective Dorsal Rhizotomy (SDR): Assessment for Nationally Funded Centre Status (A report by the Medical Services Advisory Committee to the Australian Health Ministers' Advisory Council). 1-82.
15. Narayanan UG and Howard AW. (2009) Selective dorsal rhizotomy in the management of children with spastic cerebral palsy (protocol). Cochrane Database of Systematic Reviews

Appendix A: Additional papers on selective dorsal rhizotomy for spasticity in cerebral palsy

The following table outlines the studies that are considered potentially relevant to the overview but were not included in the main data extraction table (table 2). It is by no means an exhaustive list of potentially relevant studies.

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
McLaughlin JF, Bjornson KF, Astley SJ et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Developmental Medicine & Child Neurology 1998 Apr; 40:220-232.	RCT n = 38 (21 SDR +PT vs 17 PT only) Follow-up= 2 years	SDR + PT provided a greater mean reduction in spasticity than PT only ($p = 0.02$)	Included in McLaughlin (2002) meta analysis in Table 2 [Reported in appendix A in original overview]
Graubert C, Song KM, McLaughlin JF et al. (2000) Changes in gait at 1 year post-selective dorsal rhizotomy: results of a prospective randomized study. Journal of pediatric orthopedics 20:496-500.	RCT n = 32 (18 SDR+PT vs 14 PT only) Follow-up = 1 year	Changes in ankle dorsiflexion, foot progression angle and hip and knee extension were greater with SDR + PT than PT only ($p < 0.05$)	Same cases as those included in McLaughlin (1998) study above [Reported in appendix A in original overview]
Steinbok P, Reiner AM, Beauchamp R et al. (1997) A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Developmental Medicine and Child Neurology 39:178-184.	RCT n = 30 (15 SPR + PT vs 15 PT only) Follow-up = 9 months	Gross motor function measure improved significantly more in the SDR group (11.3%) than the physiotherapy group (5.2%) ($p = 0.007$). Significant improvements in spasticity ($p < 0.001$) and range of movement ($p < 0.001$) were noted in the SPR + PT group in comparison with the PT-only group.	Included in McLaughlin (2002) meta analysis in Table 2 [Reported in appendix A in original overview]
Wright FV, Sheil EMH, Drake JM et al. (1998) Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: A randomised controlled trial. Developmental Medicine and Child Neurology 40:239-247.	RCT n = 24 (12 SDR + PT vs 12 PT only) Follow-up = 1 year	Gross motor function measure improved significantly more in the SDR group (12.1%) than the physiotherapy group (4.4%) ($p < 0.02$)	Included in McLaughlin (2002) meta analysis in Table 2 [Reported in appendix A in original overview]

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
Abbott R. (1992) Complications with selective posterior rhizotomy. <i>Pediatric Neurosurgery</i> 18:43-47. AND Abbott R, Johann-Murphy M, Shiminski-Maher T et al. (1993) Selective dorsal rhizotomy: outcome and complications in treating spastic cerebral palsy. <i>Neurosurgery</i> 33:851-857.	Case series n = 200 for efficacy outcome and 250 for safety Follow-up = 12 months for efficacy outcomes and up to 2+ years for safety outcomes	Spasticity was significantly reduced in ambulatory and non-ambulatory patients. Severe postoperative complications experienced by 15% of patients. Complications: <ul style="list-style-type: none"> • Intraoperative bronchospasm: 5% (13/250) • Aspiration pneumonia: 1% (3/250) • Urinary retention 5% (13/250) • Constipation: 20% (49/250) • Ileus: 1% (3/250) • Severe postoperative pain: 58% (145/250) • Dysthaesia: 40% (100/250) • Proprioceptive loss: 1% (3/250) • Pain / temperature loss: 1% (2/250) 	Old study [Kim 2001 is a more up to date case series of a similar size] [included in table 2 in original overview]
Chicoine MR, Park TS, and Kaufman BA. (1997) Selective dorsal rhizotomy and rates of orthopedic surgery in children with spastic cerebral palsy. <i>Journal of Neurosurgery</i> 86:34-39.	Case series n = 178 Follow-up = 44 months	Children treated later with SDR had a higher rate of subsequent orthopaedic surgery than those treated younger	Larger studies are included in table 2 [Reported in appendix A in original overview]
Kim HS, Steinbok P, and Wickenheiser D. (2006) Predictors of poor outcome after selective dorsal rhizotomy in treatment of spastic cerebral palsy. <i>Childs Nervous System</i> 22:60-66.	Case series n = 178 Follow-up = 44 months	6.3% (11/178) had a poor outcome. Type of cerebral palsy ($p < 0.001$) and intellectual delay ($p = 0.015$) were significant predictors of outcome	Larger studies are included in table 2
O'Brien DF, Park TS, Puglisi JA et al. (2005) Orthopedic surgery after selective dorsal rhizotomy for spastic diplegia in relation to ambulatory status and age. <i>Journal of Neurosurgery</i> 103:5-9.	Case series n = 158 Follow-up = 7.5 years	Orthopaedic surgery is more likely in patients destined to be non-ambulators.	Larger studies are included in table 2 [Reported in appendix A in original overview]

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
Steinbok P and Schrag C. (1998) Complications after selective posterior rhizotomy for spasticity in children with cerebral palsy. Pediatric Neurosurgery 28:300-313.	Case series n = 158 Follow-up = 29.5 months	Aspiration pneumonia was the most common intraoperative complication occurring in 2 patients. Perioperative complications: Sensory changes in 8.9% and transient urinary retention in 4.4%. 6 months after surgery: Back pain:10.8% Sensory changes: 13.9% Neurogenic bladder or bowel problems: 12.7%	Larger studies are included in table 2 [Reported in appendix A in original overview]
Salame K, Ouaknine GE, Rochkind S et al. (2003) Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. Israel Medical Association Journal: Imaj 5:543-546.	Case series n = 154 Follow-up = 11 years	Painful spasms alleviated in 80% of cases, and reduction of spasticity achieved in all cases	Larger studies are included in table 2 A mixed cohort of patients with spasticity only 60 had cerebral palsy. Data not analysed separately [Reported in appendix A in original overview]
Trost JP, Schwartz MH, Krach LE et al. (2008) Comprehensive short-term outcome assessment of selective dorsal rhizotomy. Developmental Medicine & Child Neurology 50:765-771.	Case series n = 136 Follow-up = 18.3 months (mean)	Spasticity improved	Larger studies are included in table 2
Peter JC and Arens LJ. (1993) Selective posterior lumbosacral rhizotomy for the management of cerebral palsy spasticity. A 10-year experience. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde. 83:745-747.	Case series n = 100 Follow-up = to 10 years	Satisfactory tone reduction in 95% of cases	Larger studies are included in table 2 [Reported in appendix A in original overview] Overlap with Langerak 2009a and Langerak 2009b
Morota N. (2007) Functional posterior rhizotomy: the Tokyo experience. Childs Nervous System 23:1007-1014.	Case series n = 98 Follow-up = 1+ years	39% (20/51) followed for 1+ year showed improved locomotion after functional posterior rhizotomy 59% (30/51) demonstrated suprasegmental effects after FPR.	Larger studies are included in table 2
Konya D, Gercek A, Dagcinar A et al. (2009)	Case series	Severity of spasticity reduced (mean)	Larger studies are included in table 2

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
Prevention of brisk hyperactive response during selective dorsal rhizotomy in children with spasticity: isoflurane versus sevoflurane maintenance anesthesia. Journal of Clinical Neuroscience 16:241-245	n = 54 Follow-up = 30 days	Ashworth score dropped from 3.4 to 1.77, p < 0.001)	
Grunt S, Becher JG, van SP et al. (2010) Preoperative MRI findings and functional outcome after selective dorsal rhizotomy in children with bilateral spasticity. Childs Nervous System 26:191-198.	Case series n = 36 Follow-up: 5 years and 4 months (mean)	The best improvement in gross motor function was seen in patients with normal MRI, and a slight improvement was seen in patients with hydrocephalus.	Larger studies are included in table 2
Nordmark E, Josenby AL, Lagergren J et al. (2008) Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatrics 8:54-	Case series n = 35 Follow-up = 5 years	Muscle tone was immediately reduced in adductors, hamstrings and dorsiflexors (p < 0.001) with no recurrence of spasticity over 5 years.	Larger studies are included in table 2
Chan SH, Yam KY, Yiu-Lau BP et al. (2008) Selective dorsal rhizotomy in Hong Kong: multidimensional outcome measures. Pediatric Neurology 39:22-32.	Case series n = 20 Follow-up = 12 months	Statistically significant reduction in spasticity, functional improvements in mobility and self care and increased participation in social situations	Larger studies are included in table 2
Cole GF, Farmer SE, Roberts A et al. (2007) Selective dorsal rhizotomy for children with cerebral palsy: the Oswestry experience. Archives of Disease in Childhood 92:781-785.	Case series n = 19 Follow-up = 18 months	UK study Children walked on average 0.15 m/s faster with length step improvement of 0.11m after SDR. 0.3 grade improvement in knee extension power. 78.9% (15/19) children improved by at least one level on the GMFCS.	Larger studies are included in table 2

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
Horinek D, Hoza D, Cerny R et al. (2008) Two cases of improvement of smooth pursuit eye movements after selective posterior rhizotomy. <i>Childs Nervous System</i> 24:1283-1288.	Case reports n = 4 Follow-up = 6-12 weeks	Improvement in eye response to stimulus following SPR in 2 patients due to suppression of spontaneous fixation nystagmus	Larger studies are included in table 2
Grunt S, van der Knaap MS, van Ouwerkerk WJ et al. (2008) Effectiveness of selective dorsal rhizotomy in 2 patients with progressive spasticity due to neurodegenerative disease. <i>Journal of Child Neurology</i> 23:818-822.	Case reports n = 2 Follow-up = 3 years	Leg spasticity effectively and persistently reduced in both patients, however, spasticity of the arms and other motor disturbances such as spontaneous extension spasm and ataxia increased gradually over time.	Larger studies are included in table 2
Albright AL and Tyler-Kabara EC. (2007) Combined ventral and dorsal rhizotomies for dystonic and spastic extremities. Report of six cases. <i>Journal of Neurosurgery</i> 107:Suppl-7.	Case reports n = 6 (only 2 related to cerebral palsy) Follow-up = 3 years and 6 months	Case 1: no hypertonicity after procedure and care was significantly easier. Case 2: No spasticity or dystonia in lower extremities following procedure. Care became significantly easier and comfort improved.	Larger studies are included in table 2
Spijker M, Strijers RL, van Ouwerkerk WJ et al. (2009) Disappearance of spasticity after selective dorsal rhizotomy does not prevent muscle shortening in children with cerebral palsy: a case report. <i>Journal of Child Neurology</i> 24:625-627	Case reports n = 1 Follow-up = 5 years	SDR improved walking abilities however the patient did develop muscle shortening during growth.	Larger studies are included in table 2
Sitthinamsuwan B, Chanvanitkulchai K, Nunta-Aree S et al. (2010) Combined ablative neurosurgical procedures in a patient with mixed spastic and dystonic cerebral palsy. <i>Stereotactic & Functional Neurosurgery</i> 88:187-192.	Case report n = 1 Follow-up: 1 year	Spasticity and cervical dystonia totally disappeared following SDR plus selective peripheral denervation and microsurgical dorsal root entry zone lesion.	Larger studies are included in table 2

Appendix B: Related NICE guidance for selective dorsal rhizotomy for spasticity in cerebral palsy

Guidance	Recommendations
Interventional procedures	<p>Selective dorsal rhizotomy for spasticity in cerebral palsy. NICE interventional procedures guidance 195 (2006) [current guidance]</p> <p>1.1 Current evidence on the safety of selective dorsal rhizotomy (SDR) for spasticity in cerebral palsy appears adequate; however, there is evidence of only limited efficacy. Therefore, the procedure should not be used without special arrangements for consent and for audit or research.</p> <p>1.2 Clinicians wishing to undertake SDR for spasticity in cerebral palsy should take the following actions.</p> <ul style="list-style-type: none"> o Inform the clinical governance leads in their Trusts. o Ensure that patients or their parents/carers understand the uncertainty about the efficacy of this procedure, that it is irreversible and that there is a risk of serious complications. They should also be counselled on the extensive physiotherapy and rehabilitation required after this procedure and clinicians should provide them with clear written information. Use of the Institute's information for patients ('Understanding NICE guidance') is recommended (available from www.nice.org.uk/IPG195publicinfo). o Audit and review clinical outcomes of all patients having SDR for spasticity in cerebral palsy (see section 3.1). <p>1.3 Patient selection should be carried out in the context of a multidisciplinary team with specialist expertise in various treatment options for spasticity in patients with cerebral palsy. This should normally include a physiotherapist, a paediatrician, an orthopaedic surgeon and a neurosurgeon.</p> <p>1.4 Further evidence on the efficacy outcomes of the procedure will be useful. The Institute may review the procedure upon publication of further evidence.</p>

Appendix C: Literature search for selective dorsal rhizotomy for spasticity in cerebral palsy

Database	Date searched	Version/files
Cochrane Database of Systematic Reviews – CDSR (Cochrane Library)	27/07/2010	July, 2010
Database of Abstracts of Reviews of Effects – DARE (CRD website)	27/07/2010	n/a
HTA database (CRD website)	27/07/2010	n/a
Cochrane Central Database of Controlled Trials – CENTRAL (Cochrane Library)	27/07/2010	July, 2010
MEDLINE (Ovid)	27/07/2010	1950 to July Week 2 2010
MEDLINE In-Process (Ovid)	27/07/2010	July 26, 2010
EMBASE (Ovid)	27/07/2010	1980 to 2010 Week 29
CINAHL (NLH Search 2.0)	27/07/2010	n/a
Zetoc	27/07/2010	n/a

Websites	Date searched	Title, year and link
NICE ('published' and 'in development' guidance)	07/07/2009	Selective dorsal rhizotomy for spasticity in cerebral palsy , 2005
FDA (MAUDE database)	07/07/2009	Nothing found.
ASERNIP	07/07/2009	Nothing found.
ANZHSN	07/07/2009	Nothing found.
National Institute for Health Research Clinical Research Network Coordinating Centre (NIHR CRN CC) Portfolio Database	07/07/2009	Nothing found.
Current Controlled Trials <i>metaRegister of Controlled Trials - mRCT</i>	07/07/2009	Phase II Randomized Study of Selective Dorsal Rhizotomy and Physiotherapy Vs Physiotherapy Alone for Spastic Diplegia
Clinicaltrials.gov	07/07/2009	Wavelet Analysis of Electromyography (EMG) in Cerebral Palsy
General internet search	07/07/2009	Nothing found.

The following search strategy was used to identify papers in MEDLINE. A similar strategy was used to identify papers in other databases.

1	Cerebral Palsy/
2	(cerebr* adj3 pals\$).tw.
3	spasticit*.tw.
4	(spastic* adj3 diplegia*).tw.
5	(spastic* adj3 quadripleg*).tw.
6	Quadriplegia/
7	Muscle Spasticity/
8	(increase* adj3 muscle* adj3 tone*).tw.
9	CP.tw.
10	(little* adj3 diseas*).tw.
11	tetraplegia*.tw.
12	quadripare*.tw.
13	(lock* adj3 in adj3 syndrom*).tw.
14	Muscle Rigidity/
15	(muscle* adj3 rigidit*).tw.
16	gegenhalten*.tw.
17	or/1-16
18	exp Rhizotomy/
19	Rhizotom*.tw.
20	((spin* or sensor*) adj3 nerve* adj3 interrupt*).tw.
21	or/18-20
22	(dors* or posterior or functional).tw.
23	Ganglia, Spinal/
24	(gangli* adj3 spin*).tw.
25	or/22-24

26	21 and 25
27	17 and 26
28	limit 27 to ed=20060101-20090703